FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283698841> ?p ?o ?g. }

• W4283698841 endingPage "554" @default.
• W4283698841 startingPage "541" @default.
• W4283698841 abstract "PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for younger patients and several chemoimmunotherapy regimens for older patients. Continuous debates exist on the role of ASCT in younger patients and maintenance rituximab (MR) after bendamustine plus rituximab (BR). METHODS Retrospective data from 4,216 patients with mantle cell lymphoma in the Flatiron Health electronic record-derived deidentified database diagnosed between 2011 and 2021, mostly in US community oncology settings, were evaluated for treatment patterns and outcomes. The efficacy findings with ASCT and MR were validated in an independent cohort of 1,168 patients from 12 academic centers. RESULTS Among 3,614 patients with documented 1L treatment, BR was the most used. Among 1,265 patients age < 65 years, 30.5% received cytarabine-based induction and 23.5% received ASCT. There was no significant association between ASCT and real-world time to next treatment (hazard ratio [HR], 0.84; 95% CI, 0.68 to 1.03; P = .10) or overall survival (HR, 0.86; 95% CI, 0.63 to 1.18; P = .4) among ASCT-eligible patients. Among MR-eligible patients, MR after BR versus BR alone was associated with a longer real-world time to next treatment (HR, 1.96; 95% CI, 1.61 to 2.38; P < .001) and overall survival (HR, 1.51; 95% CI, 1.19 to 1.92; P < .001). The efficacy findings were consistent in the validation cohort. CONCLUSION In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone." @default.
• W4283698841 created "2022-06-30" @default.
• W4283698841 creator A5000177686 @default.
• W4283698841 creator A5006235077 @default.
• W4283698841 creator A5007477825 @default.
• W4283698841 creator A5014007447 @default.
• W4283698841 creator A5024389256 @default.
• W4283698841 creator A5033714799 @default.
• W4283698841 creator A5040141808 @default.
• W4283698841 creator A5042306196 @default.
• W4283698841 creator A5043541884 @default.
• W4283698841 creator A5045731423 @default.
• W4283698841 creator A5047540200 @default.
• W4283698841 creator A5069054551 @default.
• W4283698841 creator A5075085884 @default.
• W4283698841 creator A5086354986 @default.
• W4283698841 creator A5089206024 @default.
• W4283698841 date "2023-01-20" @default.
• W4283698841 modified "2023-10-12" @default.
• W4283698841 title "Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts" @default.
• W4283698841 cites W1996537666 @default.
• W4283698841 cites W2056952913 @default.
• W4283698841 cites W2124432094 @default.
• W4283698841 cites W2130669641 @default.
• W4283698841 cites W2158945674 @default.
• W4283698841 cites W2162109567 @default.
• W4283698841 cites W2169209759 @default.
• W4283698841 cites W2193278586 @default.
• W4283698841 cites W2430862255 @default.
• W4283698841 cites W2499257614 @default.
• W4283698841 cites W2760635695 @default.
• W4283698841 cites W2803800538 @default.
• W4283698841 cites W2906765096 @default.
• W4283698841 cites W2908057799 @default.
• W4283698841 cites W2937620616 @default.
• W4283698841 cites W2945874655 @default.
• W4283698841 cites W2963921953 @default.
• W4283698841 cites W2967365762 @default.
• W4283698841 cites W2991957155 @default.
• W4283698841 cites W3046714011 @default.
• W4283698841 cites W3092023433 @default.
• W4283698841 cites W3116988381 @default.
• W4283698841 cites W3118661188 @default.
• W4283698841 cites W3134097844 @default.
• W4283698841 cites W3162883085 @default.
• W4283698841 cites W3172314389 @default.
• W4283698841 cites W3185036897 @default.
• W4283698841 cites W3194141756 @default.
• W4283698841 cites W3194293108 @default.
• W4283698841 cites W3200042771 @default.
• W4283698841 doi "https://doi.org/10.1200/jco.21.02698" @default.
• W4283698841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35763708" @default.
• W4283698841 hasPublicationYear "2023" @default.
• W4283698841 type Work @default.
• W4283698841 citedByCount "17" @default.
• W4283698841 countsByYear W42836988412022 @default.
• W4283698841 countsByYear W42836988412023 @default.
• W4283698841 crossrefType "journal-article" @default.
• W4283698841 hasAuthorship W4283698841A5000177686 @default.
• W4283698841 hasAuthorship W4283698841A5006235077 @default.
• W4283698841 hasAuthorship W4283698841A5007477825 @default.
• W4283698841 hasAuthorship W4283698841A5014007447 @default.
• W4283698841 hasAuthorship W4283698841A5024389256 @default.
• W4283698841 hasAuthorship W4283698841A5033714799 @default.
• W4283698841 hasAuthorship W4283698841A5040141808 @default.
• W4283698841 hasAuthorship W4283698841A5042306196 @default.
• W4283698841 hasAuthorship W4283698841A5043541884 @default.
• W4283698841 hasAuthorship W4283698841A5045731423 @default.
• W4283698841 hasAuthorship W4283698841A5047540200 @default.
• W4283698841 hasAuthorship W4283698841A5069054551 @default.
• W4283698841 hasAuthorship W4283698841A5075085884 @default.
• W4283698841 hasAuthorship W4283698841A5086354986 @default.
• W4283698841 hasAuthorship W4283698841A5089206024 @default.
• W4283698841 hasBestOaLocation W42836988412 @default.
• W4283698841 hasConcept C126322002 @default.
• W4283698841 hasConcept C141071460 @default.
• W4283698841 hasConcept C143998085 @default.
• W4283698841 hasConcept C207103383 @default.
• W4283698841 hasConcept C2776694085 @default.
• W4283698841 hasConcept C2777525834 @default.
• W4283698841 hasConcept C2778041864 @default.
• W4283698841 hasConcept C2779050716 @default.
• W4283698841 hasConcept C2779338263 @default.
• W4283698841 hasConcept C2780653079 @default.
• W4283698841 hasConcept C2780790343 @default.
• W4283698841 hasConcept C2781442060 @default.
• W4283698841 hasConcept C2911091166 @default.
• W4283698841 hasConcept C44249647 @default.
• W4283698841 hasConcept C71924100 @default.
• W4283698841 hasConcept C72563966 @default.
• W4283698841 hasConceptScore W4283698841C126322002 @default.
• W4283698841 hasConceptScore W4283698841C141071460 @default.
• W4283698841 hasConceptScore W4283698841C143998085 @default.
• W4283698841 hasConceptScore W4283698841C207103383 @default.
• W4283698841 hasConceptScore W4283698841C2776694085 @default.
• W4283698841 hasConceptScore W4283698841C2777525834 @default.
• W4283698841 hasConceptScore W4283698841C2778041864 @default.
• W4283698841 hasConceptScore W4283698841C2779050716 @default.

• next